Serum endocan levels in non-ST segment elevation myocardial infarction patients
Clinical Scorecard: Serum Levels of Endocan in Patients with Non-ST-Segment Elevation Myocardial Infarction
At a Glance
| Category | Detail |
|---|
| Condition | Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) |
| Key Mechanisms | Endothelial dysfunction and inflammation |
| Target Population | Patients diagnosed with NSTEMI undergoing coronary angiography |
| Care Setting | Emergency department and coronary angiography unit |
Key Highlights
- Serum endocan levels are significantly higher in NSTEMI patients with clinically significant coronary stenosis.
- Endocan is independently associated with angiographic severity but does not reflect myocardial injury.
- High-sensitivity troponin levels do not discriminate between critical and non-significant coronary stenosis.
- Endocan showed good discriminatory ability to distinguish between patients with and without clinically significant coronary stenosis (AUC = 0.826).
- Systemic factors such as age, diabetes, and smoking may contribute to elevated endocan levels.
Guideline-Based Recommendations
Diagnosis
- Utilize serum endocan levels as a biomarker for assessing coronary stenosis severity in NSTEMI patients.
Management
- Consider endocan levels in conjunction with other biomarkers for risk stratification in NSTEMI.
Monitoring & Follow-up
- Monitor serum endocan levels to evaluate endothelial dysfunction in NSTEMI patients.
Risks
- Elevated endocan levels may indicate increased risk of clinically significant coronary stenosis.
Patient & Prescribing Data
81 NSTEMI patients undergoing coronary angiography
Endocan levels correlate with inflammation parameters and may guide therapeutic decisions.
Clinical Best Practices
- Incorporate endocan measurement in the diagnostic workup for NSTEMI patients.
- Assess systemic inflammatory markers alongside endocan for a comprehensive evaluation.
Related Resources & Content
